Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16795490 | 0.87 | HTT (0.32) | HTTMEN1KMT2AHPGD | |
| SCHEMBL16795471 | 0.87 | HTT (0.32) | HTTMEN1KMT2AHPGD | |
| SCHEMBL18180590 | 0.87 | HTT (0.32) | HTTMEN1KMT2AHPGD | |
| SCHEMBL12139932 | 0.86 | TRPM8 (0.34) | SMYD3ALDH1A1TRPM8L3MBTL1 | |
| SCHEMBL10210966 | 0.86 | TRPM8 (0.34) | SMYD3ALDH1A1TRPM8L3MBTL1 | |
| SCHEMBL14950802 | 0.84 | L3MBTL1 (0.33) | SMYD3ALDH1A1TRPM8L3MBTL1 | |
| SCHEMBL18467491 | 0.84 | L3MBTL1 (0.33) | SMYD3ALDH1A1TRPM8L3MBTL1 | |
| SCHEMBL18467490 | 0.84 | L3MBTL1 (0.33) | SMYD3ALDH1A1TRPM8L3MBTL1 | |
| SCHEMBL18467489 | 0.84 | L3MBTL1 (0.33) | SMYD3ALDH1A1TRPM8L3MBTL1 | |
| SCHEMBL14950801 | 0.84 | L3MBTL1 (0.33) | SMYD3ALDH1A1TRPM8L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160311806-A1 | 4,4'-BIPHENYLDIYL-BIS-(1 H-IMIDAZOLYL) DERIVATIVES AS HEPATITIS HCV INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311806-A1 | 4,4'-BIPHENYLDIYL-BIS-(1 H-IMIDAZOLYL) DERIVATIVES AS HEPATITIS HCV INHIBITORS | HAVCR2, FABP1, PYGL | HTT 4452/4885MEN1 4872/4885KMT2A 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.